Application of dioscin in preventing and treating diabetic complications

A technology of diosgenin and diabetes, which is applied in the field of medicine and can solve the problems that the role of chronic complications of diabetes has not been reported.

Inactive Publication Date: 2011-05-11
INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Its effect on chronic complication

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of dioscin in preventing and treating diabetic complications
  • Application of dioscin in preventing and treating diabetic complications
  • Application of dioscin in preventing and treating diabetic complications

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0080] Example 1. Inhibitory effect of diosgenin on AR activity of normal rat lens

[0081] Rat lens aldose reductase (Aldose reductase, AR) extraction Take -80°C short-term frozen or fresh rat lens in EP tubes, add 400 μl pre-cooled deionized water to each lens, and ultrasonically break under ice bath (200W ×10s / time×3 times) until the entire lens is completely broken into a milky white suspension, centrifuge at 4°C (15,000g×30min), discard the precipitate, and use the supernatant for the experiment.

[0082] The inhibitory effect of diosgenin on normal rat lens AR was extracted from normal rat lens aldose reductase, with Epalrestat as positive reference, NADPH as coenzyme, DL-glyceraldehyde as substrate, blank well, NADPH control well, NADPH For metabolic wells, drug wells and drug blank wells, NADPH and NADPH-DL glyceraldehyde buffers were freshly prepared under ice bath. Firstly, a pre-experiment (blank well, NADPH well and NADPH metabolism well) was carried out, and afte...

Embodiment 2

[0084] Embodiment 2, the effect of diosgenin on the osmotic expansion of the lens of isolated cultured rats

[0085]Rat lenses were cultured in vitro from adult healthy male SD rats. Immediately after decapitation, the entire eyeball was taken out, soaked in 75% alcohol for 10 minutes, then transferred to an ultra-clean bench, and the eyeball was washed 3 times with sterilized artificial aqueous humor. Carefully remove the entire lens, roll it gently to remove the vitreous body on the surface of the lens, and then transfer it to a 24-well plate, in low sugar (1g / L), phenol red-free, serum-free DMEM medium, 37 ° C, 5% CO 2 After pre-cultivation under sterile conditions for 6 hours, 10 μl medium was taken for protein quantification by the Coomassie Brilliant Blue method, and the lens that was completely transparent and the protein content of the medium was less than 100 μg / ml was selected as the undamaged lens during the operation for subsequent experiments. The effect of diosge...

Embodiment 3

[0094] Embodiment 3, the impact of oral administration of diosgenin on cataract in galactose rats

[0095] experimental design

[0096] Set normal group, galactose model group and different concentrations of dioscin groups (DG 100, 200, 0.1%), n=10. Oral administration was adopted in the experiment. Rats in DG(100, 200) groups were intragastrically administered at doses of 100 and 200 mg / kg respectively, and rats in DG-0.1% group continued to drink 0.1% diosgenin solution. Rats in the normal group and the model group were given the same amount of normal drinking water by intragastric administration for 15 days.

[0097] Experimental operation

[0098] 20-day-old normal male Wistar pups with completely transparent lenses were randomly divided into 5 groups and administered orally. From 22 days old, the rats in the model group and the drug-administered group were given 12.5% ​​galactose solution from the 1st to the 7th day For feeding, 10% galactose solution was given on the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses that dioscin has certain inhibition activity to rat lens AR, has certain delaying function to both galactose cataract and diabetic cataract, and can obviously reduce content of albumin in diabetic rat urine. So that the dioscin can prevent, delay and/or treat diabetic complications, particularly diseases, such as sugar cataract, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy and the like.

Description

technical field [0001] The invention relates to the use of diosgenin for preventing, alleviating and / or treating chronic complications of diabetes, especially sugar cataract, diabetic retinopathy, diabetic nephropathy and diabetic neuropathy, and belongs to the technical field of medicine. Background technique [0002] Since the end of the last century, diabetes has become a global epidemic, and its incidence has been increasing year by year. Although there are many effective hypoglycemic drugs, few people can consistently control blood sugar within a safe range. Chronic complications will appear after 10 years. It mainly affects tissues and organs such as lens, kidney, retina and peripheral nerves. Although different chronic complications of diabetes have their own characteristics, they have similar pathological processes. [0003] The polyol pathway is an important link in the occurrence of chronic complications of diabetes. This pathway involves two enzymes-aldose reduct...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61P3/10A61P27/12A61P27/02A61P13/12A61P25/00
Inventor 申竹芳冀立霞高丽辉李彩娜沈宁刘泉环奕
Owner INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap